Arrowhead Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on March 12, 2025. The filing covers the submission of matters to a vote of security holders, including director elections, executive compensation advisory votes, auditor ratification, and the frequency of future compensation votes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (January 17, 2025), the Company had 125,073,046 shares of common stock outstanding. At the meeting, 102,744,508 shares were present or represented by proxy. All four proposals submitted to stockholders passed.
- Election of Directors: All eight nominees were elected. Douglas Ingram received the highest number of "Against" votes (13,843,071) compared to other nominees, though he was still elected.
- Executive Compensation (Say-on-Pay): Approved with 75,327,072 votes For and 7,389,926 votes Against.
- Frequency of Say-on-Pay Votes: Stockholders voted to hold these advisory votes annually (79,893,615 votes for 1 year).
- Auditor Ratification: KPMG LLP was ratified as the independent auditor for the fiscal year ended September 30, 2025, with 100,977,999 votes For.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the elevated "Against" votes for director Douglas Ingram (13.8 million votes) compared to other board members.
- Confirm the Company's cash position and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Review the full proxy statement for details on the executive compensation package approved by stockholders.
- Note that the next fiscal year end is September 30, 2025, as ratified by the auditor vote.